Chronic Lymphocytic Leukemia research hub
9 indexed studies · 9 currently recruiting
- not yet recruiting
variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway
This study looks at how UK doctors refer people with Chronic Lymphocytic Leukaemia (CLL) to specialists. We want to understand differences in care and find ways to improve how and when patients get referred, especially in the West Midlands.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This study looks at two drugs called dabrafenib and trametinib for various cancers with a specific gene change (BRAF V600). These drugs are already approved for some cancers and researchers want to see if they can help people with other rare cancers or cancers with this same change.
United Kingdom - recruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
United States · France · Spain - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This study is testing a cancer drug called capmatinib to see if it can help adults with different types of cancer that share a specific genetic change (MET mutation). It's already approved for some lung cancers, and now researchers want to know if it works for other cancers too.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This study is testing a drug called entrectinib for different cancers in adults and children. It focuses on cancers with a specific change in their cells, called ROS1 gene fusion, to see if entrectinib can be a new treatment option.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This study is testing a drug called alectinib for different types of cancer that have a special gene change called ALK. It's already used for some lung cancers, and now doctors want to see if it can help other cancers with the same change.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This study is for adults with specific cancers that have a change called BRAF V600. It's testing if two drugs, vemurafenib and cobimetinib, already used for a type of skin cancer, can help treat these other cancers. The goal is to find new treatments for patients.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
The DETERMINE trial is testing if existing cancer medicines can help people with rare cancers or common cancers with rare genetic changes. It includes adults, teenagers, and children. The goal is to find new ways to treat cancer and make these treatments available through the NHS.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This study is testing if two drugs, trastuzumab and pertuzumab, can treat different types of cancer beyond breast cancer. These drugs work by targeting a specific change in cancer cells called HER2. It's for people aged 12 and over with HER2-positive cancers.
United Kingdom